2021 Deal Flow Public Companies 
The Motley Fool
SEPTEMBER 9, 2024
Furthermore, some BDCs, such as Ares Capital, offer more sophisticated financing solutions -- making them appealing to larger public companies as well. Category 2018 2019 2020 2021 2022 2023 Six Months Ended June 30, 2024 Net Investment Income Per Share $1.19 $1.41 $1.39 $1.29 $1.48 $2.09 $1.01 Well, not exactly.
The Motley Fool
FEBRUARY 9, 2024
We finished 2023 on a strong note with another consecutive quarter of management fee and FRE growth, 11 for 11 since we've been a public company, against a market backdrop that has been exceptionally volatile and uncertain. Since our listing in May of 2021, total return for our shareholders has been over 60%. Thank you, Ann.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Motley Fool
OCTOBER 11, 2024
iShares is leading the industry in global flows with approximately $250 billion through the third quarter and historically sees upwards of 40% of its total annual flows in Q4. iShares' fixed-income ETF assets now stand at over $1 trillion, nearly 40% higher than at year-end 2021. And Aladdin. Finally, fixed income.
The Big Picture
OCTOBER 31, 2023
Just really a fascinating history from, from a private company to a public company back to a, a partnership. He is uniquely situated because he has run both public mutual funds as well as privates, including late stage venture private equity credit down the list. They’ve been around literally nearly a century.
The Big Picture
JULY 2, 2024
Eva Shang : So at the time that we launched, there were already public companies that were doing litigation finance. We’ve done over 400 deals. Second fund in 2019, third fund in 2021. So in the early years we only had 10 million of assets, but we had billions of dollars of deal flow.
The Motley Fool
APRIL 18, 2024
data center REIT as a well-positioned but poorly trading public company with tremendous long-term potential. Our BREIT, BIP Infrastructure, and BPP perpetual strategies acquired the company for $10 billion in 2021, and its lease capacity has already grown sixfold in less than three years.
The Motley Fool
FEBRUARY 20, 2024
In 2021, we launched a second long-range R&D effort to build a highly differentiated platform for the creation of precision T-cell engagers for indications in cancer and autoimmunity. You know, as I said in my prepared remarks, we launched that in about 2021. ABCL635 and ABCL575 are both on track to enter clinical trials in 2025.
Expert insights. Personalized for you.
246 
Let's personalize your content